BCMLT
ZVRA icon

Beacon Capital Management LLC (Tennessee)’s Zevra Therapeutics ZVRA Stock Holding History

Beacon Capital Management LLC (Tennessee)’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-31
Closed -$152 – 1228
2024
Q2 		$152 Hold
31
– – ﹤0.01% 1029
2024
Q1 		$180 Hold
31
– – ﹤0.01% 1032
2023
Q4 		$149 Hold
31
– – ﹤0.01% 960
2023
Q3 		$158 Hold
31
– – ﹤0.01% 999
2023
Q2 		$158 Hold
31
– – ﹤0.01% 999
2023
Q1 		$171 Hold
31
– – ﹤0.01% 921
2022
Q4 		$142 Hold
31
– – ﹤0.01% 974
2022
Q3 		$0 Hold
31
– – ﹤0.01% 992
2022
Q2 		$0 Hold
31
– – ﹤0.01% 964
2022
Q1 		$0 Buy
+31
New +$197 ﹤0.01% 964

Other funds holding ZVRA

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Beacon Capital Management LLC (Tennessee)'s ZVRA Position: Q3 2024 in Review

Beacon Capital Management LLC (Tennessee) sold out of Zevra Therapeutics (ZVRA) in Q3 2024, closing a stake of 31 shares — an estimated $152 sold.

Beacon Capital Management LLC (Tennessee) first reported a position in ZVRA in Q1 2022 and held it in 10 quarters. The position peaked at $180 in Q1 2024. 108 funds tracked by Wall St. Rank hold ZVRA as of Q3 2024.

  • Beacon Capital Management LLC (Tennessee) reported no remaining Zevra Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Beacon Capital Management LLC (Tennessee) sold 31 Zevra Therapeutics shares in Q3 2024, an estimated $152.
  • Beacon Capital Management LLC (Tennessee) first reported a position in Zevra Therapeutics in Q1 2022 and held it in 10 quarters.
  • Beacon Capital Management LLC (Tennessee)'s Zevra Therapeutics position peaked at $180 in Q1 2024.
  • 108 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2024.

Based on Beacon Capital Management LLC (Tennessee)'s 13F filing for Q3 2024, filed 7 Nov 2024.